SAGE Therapeutics Inc. (SAGE)

139.93
NASDAQ : Health Technology
Prev Close 144.83
Day Low/High 139.03 / 144.88
52 Wk Low/High 79.88 / 193.56
Avg Volume 388.10K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 7.48B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trade Desk, BioLife Solutions, Sage Therapeutics: 'Mad Money' Lightning Round

Trade Desk, BioLife Solutions, Sage Therapeutics: 'Mad Money' Lightning Round

Jim Cramer looks at the Trade Desk, BioLife Solutions, Sage Therapeutics, Iron Mountain, Ventas, Service Corp. International and more.

Did You See it Coming?: Cramer's 'Mad Money' Recap (Wednesday 10/2/19)

Did You See it Coming?: Cramer's 'Mad Money' Recap (Wednesday 10/2/19)

Jim Cramer said weeks ago that it was time to raise cash. Investors shouldn't panic, he says, they should be disciplined.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on October 1, 2019, the...

Sage Therapeutics To Participate In J.P. Morgan Executive Conference Call Series

Sage Therapeutics To Participate In J.P. Morgan Executive Conference Call Series

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in an...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019, the...

Sage Therapeutics Announces The New England Journal Of Medicine Publishes Data From Phase 2 Trial With SAGE-217 In Major Depressive Disorder

Sage Therapeutics Announces The New England Journal Of Medicine Publishes Data From Phase 2 Trial With SAGE-217 In Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that the New England Journal of Medicine (NEJM)...

Sage Therapeutics To Present At The Morgan Stanley Global Healthcare Conference

Sage Therapeutics To Present At The Morgan Stanley Global Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan...

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCRH, DGSE Downgrades: ARLP, CIT, CSLT, ERIC, FTI, LE, NTZ, PICO Initiations: AFIN, BRY, BV, CCB, MYFW, SAGE, TLRY, XERS Read on to get TheStreet Quant Ratings' detailed report:

Sage Therapeutics To Present At 2019 Wedbush PacGrow Healthcare Conference

Sage Therapeutics To Present At 2019 Wedbush PacGrow Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in the...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019, the...

Sage Therapeutics Announces Clinical Updates And Progress Across Neuroscience Pipeline During "Sage FutureCast"

Sage Therapeutics Announces Clinical Updates And Progress Across Neuroscience Pipeline During "Sage FutureCast"

Today, Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host "Sage FutureCast: An R&D Portfolio Review"...

Sage Therapeutics To Report Second Quarter 2019 Financial Results On Tuesday, August 6, 2019

Sage Therapeutics To Report Second Quarter 2019 Financial Results On Tuesday, August 6, 2019

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics To Host "Sage FutureCast" Webcast

Sage Therapeutics To Host "Sage FutureCast" Webcast

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host "Sage FutureCast: An R&D and Portfolio Review" on Wednesday, July 24, 2019...

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare...

Product Shot (black) (Photo: Business Wire)

Product Shot (black) (Photo: Business Wire)

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Sage Therapeutics To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40 th Annual Global Healthcare...

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

Sage Therapeutics To Present At 2019 RBC Capital Markets Global Healthcare Conference

Sage Therapeutics To Present At 2019 RBC Capital Markets Global Healthcare Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare...

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Sage Therapeutics To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019, the Compensation Committee of Sage's Board of Directors...

Sage Therapeutics Announces First Quarter 2019 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces First Quarter 2019 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31,...

Sage Therapeutics To Report First Quarter 2019 Financial Results On Thursday, May 2, 2019

Sage Therapeutics To Report First Quarter 2019 Financial Results On Thursday, May 2, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019, the Compensation Committee of Sage's Board of...

A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me

A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me

Let's review the charts this morning.

Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)

Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)

But don't forget, says Jim Cramer, we still need a trade deal with China.

TheStreet Quant Rating: D (Sell)